<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00800046</url>
  </required_header>
  <id_info>
    <org_study_id>1436</org_study_id>
    <nct_id>NCT00800046</nct_id>
  </id_info>
  <brief_title>A Study of Percutaneous Repair of Functional Mitral Regurgitation Using the Ancora Heart, Inc. AccuCinch® Ventricular Repair System - The CINCH-2 Study</brief_title>
  <acronym>CINCH-2</acronym>
  <official_title>A Study of Percutaneous Repair of Functional Mitral Regurgitation Using the Ancora Heart, Inc. AccuCinch® Ventricular Repair System - The CINCH-2 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ancora Heart, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ancora Heart, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective single-arm study of the AccuCinch® Ventriculoplasty System in the treatment of&#xD;
      mitral valve regurgitation through subvalvular mitral repair.&#xD;
&#xD;
      Purpose: To demonstrate the safety, feasibility and potential efficacy of using the&#xD;
      AccuCinch® Ventriculoplasty System to reduce mitral valve regurgitation through subvalvular&#xD;
      mitral repair.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2008</start_date>
  <completion_date type="Actual">January 2021</completion_date>
  <primary_completion_date type="Actual">November 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety through 30 days and reduction in MR acutely and at 30 days.</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and reduction in MR at 1 year.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Mitral Regurgitation</condition>
  <condition>Mitral Valve Regurgitation</condition>
  <condition>Functional Mitral Regurgitation</condition>
  <arm_group>
    <arm_group_label>AccuCinch® Ventriculoplasty System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients meeting the enrollment criteria will be treated with the AccuCinch® Ventriculoplasty System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AccuCinch® Ventriculoplasty System</intervention_name>
    <description>Mitral valve repair due to functional disease</description>
    <arm_group_label>AccuCinch® Ventriculoplasty System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Severity of FMR: ≥ Moderate (i.e., 2+)&#xD;
&#xD;
          -  Ejection Fraction: ≥ 20% to ≤60%&#xD;
&#xD;
          -  Symptom Status: NYHA II-IVa&#xD;
&#xD;
          -  Treatment and compliance with optimal guideline directed medical therapy for heart&#xD;
             failure for at least 1 month&#xD;
&#xD;
          -  Surgical risk: Subject is eligible for cardiac surgery (specific EuroSCORE (LES or&#xD;
             ESII), STS, or comorbidities should demonstrate high risk features)&#xD;
&#xD;
          -  Completion of all qualifying diagnostic and functional tests and agrees to comply with&#xD;
             study follow-up schedule&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant organic mitral valve pathology (e.g. myxomatous degeneration, mitral valve&#xD;
             prolapse or flail leaflets)&#xD;
&#xD;
          -  Myocardial infarction or any percutaneous cardiovascular intervention, cardiovascular&#xD;
             surgery, or carotid surgery within 30 days&#xD;
&#xD;
          -  Prior surgical, transcatheter, or percutaneous mitral valve intervention&#xD;
&#xD;
          -  Untreated clinically significant coronary artery disease (CAD) requiring&#xD;
             revasularization&#xD;
&#xD;
          -  Hemodynamic instability: Hypotension (systolic pressure &lt;90 mmHg) or requirement for&#xD;
             inotropic support or mechanical hemodynamic support&#xD;
&#xD;
          -  Any planned cardiac surgery within the next 6 months (including right heart&#xD;
             procedures)&#xD;
&#xD;
          -  NYHA class (i.e., non-ambulatory) or ACC/AHA Stage D heart failure&#xD;
&#xD;
          -  Fixed pulmonary artery systolic pressure &gt;70 mmHg&#xD;
&#xD;
          -  Severe tricuspid regurgitation (per ASE guidelines and graded by the Echo Core Lab)&#xD;
&#xD;
          -  Modified Rankin Scale ≥ 4 disability&#xD;
&#xD;
          -  Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or&#xD;
             any other structural heart disease causing heart failure other than dilated&#xD;
             cardiomyopathy of either ischemic or non-ischemic etiology&#xD;
&#xD;
          -  Mitral valve area less than 4.0 cm2&#xD;
&#xD;
          -  Anatomical pathology/contraints preventing appropriate access/ implant of the&#xD;
             AccuCinch System&#xD;
&#xD;
          -  Renal insufficiency (i.e., eGFR of &lt;30ml/min/1.73m2 ; Stage 4 or 5 CKD)&#xD;
&#xD;
          -  Moderate or severe aortic valve stenosis or regurgitation or aortic valve prosthesis&#xD;
             Fluoroscopic or echocardiographic evidence of severe aortic arch calcification, mobile&#xD;
             aortic atheroma, intracardiac mass, thrombus or vegetation&#xD;
&#xD;
          -  Active bacterial endocarditis&#xD;
&#xD;
          -  History of stroke within the prior 3 months&#xD;
&#xD;
          -  Subjects in whom anticoagulation or antiplatelet therapy is contraindicated&#xD;
&#xD;
          -  Known allergy to nitinol, polyester, or polyethylene&#xD;
&#xD;
          -  Any prior true anaphylactic reaction to contrast agents; defined as known&#xD;
             anaphylactoid or other non-anaphylactic allergic reactions to contrast agents that&#xD;
             cannot be adequately pre-medicated prior to the index procedure.&#xD;
&#xD;
          -  Life expectancy &lt; 1 year due to non-cardiac conditions&#xD;
&#xD;
          -  Currently participating in another interventional investigational study&#xD;
&#xD;
          -  Implant or revision of any rhythm management device (CRT or CRTD) or implantable&#xD;
             cardioverter defibrillator within 1 month&#xD;
&#xD;
          -  Absence of CRT with class I indication criteria for biventricular pacing (left bundle&#xD;
             branch block pattern and QRS duration ≥150 ms)&#xD;
&#xD;
          -  On high dose steroids or immunosuppressant therapy&#xD;
&#xD;
          -  Female subjects who are pregnant or lactating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joachim Schofer, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Care Center Prof. Mathey, Prof. Schofer, GmbH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick Perier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Center Bad Neustadt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Freiburg-Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Immanuel Klinikum Bernau Herzzentrum Brandenburg</name>
      <address>
        <city>Bernau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.-Johannes-Hospital</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Center Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Care Center Hamburg University Cardiovascular Center</name>
      <address>
        <city>Hamburg</city>
        <zip>22527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital Santaros Klinikos</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Lithuania</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 26, 2008</study_first_submitted>
  <study_first_submitted_qc>November 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2008</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mitral valve</keyword>
  <keyword>Mitral regurgitation</keyword>
  <keyword>Functional mitral regurgitation</keyword>
  <keyword>MR</keyword>
  <keyword>FMR</keyword>
  <keyword>Heart valve</keyword>
  <keyword>Mitral valve insufficiency</keyword>
  <keyword>Valve repair</keyword>
  <keyword>Valve disorder</keyword>
  <keyword>Cardiac surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

